MRNA US60770K1079

Report

Delayed Nasdaq - 04:00 2022-07-01 pm EDT
149.95	USD		+4.97%

07/01	INSIDER SELL : Moderna	MT
06/30	Moderna Files For Canadian Regulatory Approval Of New COVID-19 Booster	MT
06/30	U.S. FDA to use existing Omicron booster data to review shots targeting new subvariants -official	RE

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

06/27/2022	06/28/2022	06/29/2022	06/30/2022	07/01/2022	Date
145.36(c)	142.19(c)	142.81(c)	142.85(c)	149.95(c)	Last
4 392 762	3 988 199	2 908 054	5 631 685	4 838 179	Volume
+0.76%	-2.18%	+0.44%	+0.03%	+4.97%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2022	22 079 M - -
Net income 2022	11 509 M - -
Net cash position 2022	18 531 M - -
P/E ratio 2022	5,50x
Yield 2022	-

Sales 2023	9 800 M - -
Net income 2023	3 215 M - -
Net cash position 2023	22 705 M - -
P/E ratio 2023	19,6x
Yield 2023	-

Capitalization	59 644 M 59 644 M -
EV / Sales 2022	1,86x
EV / Sales 2023	3,77x
Nbr of Employees	2 700
Free-Float	90,6%

More Financials

Company

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in...

Sector

Biotechnology & Medical Research

Calendar

08/03

Earnings Release

More about the company

Ratings of Moderna, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

All news about MODERNA, INC.

07/01	INSIDER SELL : Moderna	MT
06/30	Moderna Files For Canadian Regulatory Approval Of New COVID-19 Booster	MT
06/30	U.S. FDA to use existing Omicron booster data to review shots targeting new subvariants..	RE
06/30	US FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants	RE
06/30	Tweaked COVID boosters in US must target newer omicron types	AQ
06/30	Moderna Seeks Health Canada Nod For New Double-Protection Covid-19 Booster - Global New..	RE
06/30	COVID SCIENCE-Pausing methotrexate improves booster response; first-trimester of pregna..	RE
06/29	BioNTech, Pfizer to starting testing universal coronavirus vaccine in H2	RE
06/29	Taiwan to receive first doses of Novavax COVID vaccine this week	RE
06/28	Pfizer, Moderna to be ready with BA.1-specific COVID boosters	RE
06/28	FDA advisers recommend updating COVID booster shots for fall	AQ
06/27	INSIDER SELL : Moderna	MT
06/27	US grapples with whether to modify COVID vaccine for fall	AQ
06/27	INSIDER SELL : Moderna	MT
06/26	Moderna Seeks Swissmedic's Approval Extension For COVID-19 Jab Against Omicron	MT

More news

News in other languages on MODERNA, INC.

07/01	VENTE D'INITIÉS : Moderna
06/30	Moderna dépose une demande d'approbation réglementaire canadienne pour le nouveau boost..
06/30	FDA bittet Impfstoffhersteller um Anpassung auf Omikron-Sublinien
06/30	Südkorea erteilt erstmals Zulassung für einheimischen Impfstoff
06/29	Taiwan recevra les premières doses du vaccin Novavax COVID cette semaine

More news

Analyst Recommendations on MODERNA, INC.

06/09	Argus Adjusts Moderna's Price Target to $180 From $200, Reiterates Buy Rating	MT
06/07	SVB Securities Adjusts Moderna's Price Target to $70 From $80, Keeps Underperform Ratin..	MT
05/18	Piper Sandler Adjusts Moderna's Price Target to $214 From $348, Reiterates Overweight R..	MT

More recommendations

Stock Trading Strategies

	MODERNA, INC. - 03/09
A support level that should be taken advantage of

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

COVID-19 vaccine scheme for world's poorest pushes for delivery slowdown